Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.52 |
| ▸ | FAAH | O00519 | 2/20 | 0.46 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 4/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | EPAS1 | Q99814 | 3/20 | 0.41 |
| ▸ | ADH1B | P00325 | 2/20 | 0.35 |
| ▸ | ADH1C | P00326 | 2/20 | 0.35 |
| ▸ | ADH1A | P07327 | 2/20 | 0.35 |
| ▸ | ADH4 | P08319 | 1/20 | 0.35 |
| ▸ | ADH7 | P40394 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.33 |
| ▸ | KDM4A | O75164 | 1/20 | 0.33 |
| ▸ | PHF8 | Q9UPP1 | 1/20 | 0.33 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.33 |
| ▸ | KDM1A | O60341 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4978224 | 1.00 | TSHR (0.52) | TSHRFAAHTRPV1HIF1ALMNA | |
| SCHEMBL294142 | 1.00 | TSHR (0.52) | TSHRFAAHTRPV1HIF1ALMNA | |
| SCHEMBL536858 | 1.00 | TSHR (0.52) | TSHRFAAHTRPV1HIF1ALMNA | |
| SCHEMBL443450 | 1.00 | TSHR (0.52) | TSHRFAAHTRPV1HIF1ALMNA | |
| SCHEMBL2523320 | 1.00 | TSHR (0.52) | TSHRFAAHTRPV1HIF1ALMNA | |
| SCHEMBL5654128 | 1.00 | TSHR (0.52) | TSHRFAAHTRPV1HIF1ALMNA | |
| SCHEMBL756048 | 1.00 | TSHR (0.52) | TSHRFAAHTRPV1HIF1ALMNA | |
| SCHEMBL15327039 | 1.00 | TSHR (0.52) | TSHRFAAHTRPV1HIF1ALMNA | |
| SCHEMBL21619221 | 1.00 | TSHR (0.52) | TSHRFAAHTRPV1HIF1ALMNA | |
| SCHEMBL9254348 | 1.00 | TSHR (0.52) | TSHRFAAHTRPV1HIF1ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 569 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021108411-A1 | MERGING C(SP3)-H ACTIVATION WITH DNA-ENCODING | THE SCRIPPS RESEARCH INSTITUTE (US) | 2021-06-03 | — | — | WO | claimed |
| US-10767198-B2 | Method for producing branched aldehydes | SYMRISE AG (DE) | 2020-09-08 | — | — | US | claimed |
| EP-3380625-B1 | METHOD FOR PRODUCING BRANCHED ALDEHYDES | SYMRISE AG (DE) | 2020-08-05 | — | — | EP | claimed |
| EP-3380625-A1 | METHOD FOR PRODUCING BRANCHED ALDEHYDES | Symrise AG (DE) | 2018-10-03 | — | — | EP | claimed |
| EP-3109254-B1 | CROSSLINKED NUCLEOSIDE AND NUCLEOTIDE | UNIV OSAKA (JP) | 2018-04-11 | — | — | EP | claimed |
| WO-2017088937-A1 | METHOD FOR PRODUCING BRANCHED ALDEHYDES | SYMRISE AG (DE) | 2017-06-01 | — | — | WO | claimed |
| US-20090285888-A1 | DERIVATIVES OF DIHYDROXYPHENYLALANINE | ELLNEUROXX LTD. (DE) | 2009-11-19 | — | — | US | claimed |
| CN-101208326-A | Derivate von dihydroxyphenylalanin | ELLNEUROXX LTD (DE) | 2008-06-25 | — | — | CN | claimed |
| EP-1879880-A2 | DIHYDROXYPHENYLALANINE DERIVATIVES | Ellneuroxx Ltd. (DE) | 2008-01-23 | — | — | EP | claimed |
| WO-2006119758-A2 | DIHYDROXYPHENYLALANINE DERIVATIVES | ELLNEUROXX LTD. (DE) | 2006-11-16 | — | — | WO | claimed |
| WO-2005030253-A9 | PHOTOCLEAVABLE DNA TRANSFER AGENT | NITTO DENKO CORP (JP) | 2005-06-02 | — | — | WO | claimed |
| WO-2004031732-A2 | NANOCRYSTALS IN LIGAND BOXES EXHIBITING ENHANCED CHEMICAL, PHOTOCHEMICAL, AND THERMAL STABILITY, AND METHODS OF MAKING THE SAME | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS (US) | 2004-04-15 | — | — | WO | claimed |
| US-6110933-A | AN ENZYME INHIBITOR TREATING PANCREATITIS, HEPATITIS, CHRONIC RENAL FAILURE, ENDOTOXIN SHOCK, GRAM-NEGATIVE SEPTIC SHOCK, ARTHRITIS, RESPIRATORY DISEASE, HEART DISEASE, ALLERGIC DISEASE, THROMBOSIS, ARTERIOSCLEROSIS, PAIN | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2000-08-29 | — | — | US | claimed |
| US-5352689-A | Rhizoxin derivatives and their use as anti-tumor agents | SANKYO COMPANY, LIMITED (JP) | 1994-10-04 | — | — | US | claimed |
| US-4714490-A | ALIPHATIC ALDEHYDE | KAO CORPORATION (JP) | 1987-12-22 | — | — | US | claimed |
| US-4074054-A | Imidazoles and 2-alkyl imidazoles and method for their manufacture | NOBEL HOECHST CHIMIE (FR) | 1978-02-14 | — | — | US | claimed |
| WO-2024135721-A1 | METHOD FOR PRODUCING PRODUCTION INTERMEDIATE, PRODUCTION INTERMEDIATE THEREOF, AND METHOD FOR PRODUCING CROSSLINKED ARTIFICIAL NUCLEIC ACID INTERMEDIATE BY USING SAME | 田辺三菱製薬株式会社 | 2024-06-27 | — | — | WO | disclosed |
| WO-2024101446-A1 | MODIFIED NUCLEOSIDE HAVING GUANIDINO STRUCTURE IN BRIDGED PART AND METHOD FOR PRODUCING OLIGONUCLEOTIDE USING SAME | ルクサナバイオテク株式会社 | 2024-05-16 | — | — | WO | disclosed |
| US-4714490-A | ALIPHATIC ALDEHYDE | KAO CORPORATION (JP) | 1987-12-22 | — | — | US | disclosed |
| US-4074054-A | Imidazoles and 2-alkyl imidazoles and method for their manufacture | NOBEL HOECHST CHIMIE (FR) | 1978-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090285888-A1 | DERIVATIVES OF DIHYDROXYPHENYLALANINE | HTT, NLN, SNCA | TSHR 2878/4885FAAH 4423/4885TRPV1 4807/4885 |
| US-10767198-B2 | Method for producing branched aldehydes | ADH5, AOX1, ALDH2 | TSHR 4597/4885FAAH 1000/4885TRPV1 4814/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.